Clearing the US and EU Regulatory Path to Product Approval – “What Similarities and Differences Exist and How Can Companies Manage the Hurdles?”

Learn how to navigate through the complexities and policy changes that biotech and nanotech products face today. Expert advice and case studies will provide valuable lessons on how policy and regulation is influencing technology in the US and EU and what companies can do to save time and cost throughout the process. Do regulatory agencies have the legal authority to make judgments on nanomaterials? Are they ready for this responsibility?

Center for Nanosciences and Nanotechnology at Universidad Nacional Autonoma de México (UNAM) Ensenada

Thursday, March 13, 2008 @ Fish & Richardson Law Offices 12390 El Camino Real San Diego, CA, 92130 from 5:30 pm - 8:30 pm

The debut of UNAM Ensenada’s Center for Nanoscience and Nanotechnology marks the trend of newly inaugurated departments focused on nanotechnology in universities around the world. UNAM is already recognized as the university with the highest concentration of researchers working on nanotechnology and some of the most ambitious projects. At UNAM Ensenada this announcement ties into an overall vision for the region that includes vinculation, innovation and economic sustainability through industrial applications of breakthrough technology.

Distinguished Speakers:

Dr. Carlos Aramburo de la Hoz
National Scientific Coordinator
UNAM, Mexico City, Mexico

Dr. Sergio Fuentes
Director UNAM Ensenada

Dr. Nina Bogdanchikova
Principal Investigator, UNAM Ensenada

Plan to attend NanoScience + Engineering, one of the largest and most important technical conferences covering developing technologies at the nanoscale, current and future applications, and the environmental, health, and safety issues that must be addressed.

This must-attend conference for the drug delivery community brings together expert speakers from the Drug Delivery, Pharmaceutical, Biotechnology, Device and Venture Capital fields. Unlike other drug delivery conferences, we offer six distinct scientific tracks covering the latest discoveries and trends in nanotechnology, transdermal, ophthalmic, oral, injectables and nasal/pulmonary delivery, while our business and science track provides practical, actionable information about the latest issues relevant to the entire drug delivery community. New this year are our extensive regulatory and compliance sessions. You’ll also find all-new topics such as prodrugs and gene therapy.